Cogent Biosciences, Inc. (COGT)
$28.09-5.67%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4.8B
- Beta
- 0.31
- P/E (TTM)
- -12.16
- Short % float
- 13.10%
- Days to cover
- 8.1
- SI change
- +7.4%
- 1W
- -7.54%
- 1M
- -15.92%
- vs SPY 1W
- -7.40%
- vs SPY 1M
- -18.43%
Industry peers
FMP comparable companies · ranked by market cap
- INCYSELLIncyte Corporation$22.9BBEARQ 13$112.79-2.46%
- TNGXSELLTango Therapeutics, Inc.$3.9BRECOVERYQ 23$23.81-8.07%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.11-4.99%
- RCUSSELLArcus Biosciences, Inc.$3.1BCRISISQ 17$24.41-7.52%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.14%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 15$16.99-15.71%
- MAZEBUYMaze Therapeutics, Inc.$1.5BRECOVERYQ 36$27.11-3.75%
- KURASELLKura Oncology, Inc.$941MCRISISQ 12$10.60-5.48%
- AVBPSELLArriVent BioPharma, Inc.$779MCRISISQ -6$16.73-2.25%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 17
- VALUE
- 7
- GROWTH
- 43
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-43.5%
REV YoY-
ROE-72.6%
EPS YoY-
ROA-45.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-12.16
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B9.02
P/FCF-
EV/EBITDA-13.06
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E45.88
ALTMAN Z-
CURR RATIO13.57
ND/EBITDA-
BETA0.31
Company news
FAQ
- What is LOPJLB’s current signal on COGT?
- LOPJLB’s latest quantitative signal on Cogent Biosciences, Inc. (COGT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is COGT in?
- Cogent Biosciences, Inc. (COGT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cogent Biosciences, Inc. (COGT) do?
- Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from…